WATCH: ‘Strain choice, dose & role are the main probiotic R&D issues'

This content item was originally published on, a William Reed online publication.

By Will Chu

- Last updated on GMT

The translation of microbiome science into commercially viable applications remains an ongoing challenge that needs addressing before consumers are able to reap the mental and physical health benefits.
Ted Dinan
Ted Dinan, professor of psychiatry at University College Cork. ©Ted Dinan

According to University College Cork’s professor of psychiatry Ted Dinan, development of a polybiotic is made all the more difficult by the uncertainty of their specific roles and subsequent chances of survival.

“The challenge initially is to make sure that these strains are not antagonising each other,”​ he explains. “They need to be co-operative if possible but certainly that they can survive together.”

“You don’t want to have a polybiotic with five strains of bacteria, of which three are knocking each other out. So by the time the polybiotic reaches the intestine there are only two strains left.”

Psychobiotic research and development

Professor Dinan, previously chair of clinical neurosciences at St. Bartholomew’s Hospital, London, has a research interest in psychobiotics. He also highlights dose considerations that despite the breadth of microbiome studies remains a matter of debate.

Douwina Bosscher
Douwina Bosscher, global R&D and nutrition sciences leader at Cargill. ©DouwinaBosscher

“We don’t know what the appropriate dosage of these psychobiotics should be​,” he said. “We tend to use 108​ - 109 ​Colony Forming Units (CFU) but there aren’t any adequate dosing studies.”

Dinan was speaking at the MyNewGut Conference in Brussels, where a host of delegates, both from industry and academia gathered to hear the results of the five-year EU funded project and the gut microbiome’s links to obesity, behavioural and lifestyle-related disorders.

A potential application of the microbiome that has stimulated interest from food makers and nutritional researchers is being able to translate causative research into evidence-based nutritional interventions that impact human health positively.

“Where we need to move forward is the need to move form associations to demonstrating causality focusing on the mechanistics ​said Douwina Bosscher, global R&D and nutrition sciences leader at Cargill.

“We can then understand what the effect is of a particular ingredient on the composition of the microbiomeand we can then determine how this impacts the health of the human being.”


Related news

Show more

Related products

show more

Whitepaper: Discover a new era in postbiotics

Whitepaper: Discover a new era in postbiotics

Content provided by DSM Nutritional Products | 28-Nov-2023 | White Paper

Postbiotic ingredients are set to open up a world of opportunities across the human health and nutrition industry, fueled by developing science demonstrating...

Taking Immune Support to a New Level

Taking Immune Support to a New Level

Content provided by AB Biotek Human Nutrition & Health | 30-Oct-2023 | White Paper

Patent-pending ABB C1® redefines immune support by addressing innate, acquired, and Trained Immunity. In 'ABB C1®: Training Now for Future Immune...

Custom Biotic Solutions for Digestive Health

Custom Biotic Solutions for Digestive Health

Content provided by ADM: Innovation that Feeds the Future | 10-Oct-2023 | White Paper

A growing body of evidence shows gut health can affect digestive health, well-being, and many health areas in between.

Related suppliers

Follow us


View more